Blinatumomab in Pediatric Acute Lymphoblastic Leukemia-From Salvage to First Line Therapy (A Systematic Review).
Manon Queudeville,Martin Ebinger +1 more
Reads0
Chats0
TLDR
In this article, a systematic review discusses all published results for blinatumomab in children as well as all ongoing clinical trials in R/R-ALL and concludes that the use of BLINATOMAB is beneficial for patients with a high risk of severe chemotherapy-associated toxicities.Abstract:
Acute lymphoblastic leukemia is by far the most common malignancy in children, and new immunotherapeutic approaches will clearly change the way we treat our patients in future years. Blinatumomab is a bispecific T-cell-engaging antibody indicated for the treatment of relapsed/refractory acute lymphoblastic leukemia (R/R-ALL). The use of blinatumomab in R/R ALL has shown promising effects, especially as a bridging tool to hematopoietic stem cell transplantation. For heavily pretreated patients, the response to one or two cycles of blinatumomab ranges from 34% to 66%. Two randomized controlled trials have very recently demonstrated an improved reduction in minimal residual disease as well as an increased survival for patients treated with blinatumomab compared to standard consolidation treatment in first relapse. Current trials using blinatumomab frontline for high-risk patients or as a consolidation treatment post-transplant will show whether efficacy is even higher in less heavily pretreated patients. Due to the distinct pattern of adverse events compared to high-dose conventional chemotherapy, blinatumomab could play an important role for patients with a risk for severe chemotherapy-associated toxicities. This systematic review discusses all published results for blinatumomab in children as well as all ongoing clinical trials.read more
Citations
More filters
Journal ArticleDOI
Low-intensity therapy cures over 40 % of children with rapid Flow-MRD responding ALL: the ALL-MB 2008 trial results
Alexander Popov,Geraldine Henze,Yu. V. Roumiantseva,O.I. Budanov,Mikhail Belevtsev,Tatiana Verzhbitskaya,E V Boyakova,Ludmila V. Movchan,G Tsaur,Maria S. Fadeeva,Svetlana Lagoyko,L. Zharikova,N.V. Myakova,Dmitry Litvinov,Olga Khlebnikova,Olga Streneva,E L Stolyarova,Natalia Ponomareva,Galina Novichkova,L Fechina,O.V. Aleinikova,Alexander Karachunskiy +21 more
TL;DR: Initial SR characteristics plus one single MRD measurement at EOI identify more than 40 % of all children with ALL who can be successfully treated with low-intensity regimens as used in the MB protocols.
Journal ArticleDOI
Blinatumomab Prior to CAR-T Cell Therapy—A Treatment Option Worth Consideration for High Disease Burden
Paweł Marschollek,Karolina Liszka,Monika Mielcarek-Siedziuk,Blanka Rybka,Renata Ryczan-Krawczyk,Anna Panasiuk,Igor Olejnik,Jowita Frączkiewicz,Iwona Dachowska-Kałwak,Agnieszka Mizia-Malarz,Tomasz Szczepański,Wojciech Młynarski,Jan Styczyński,Katarzyna Drabko,Grażyna Karolczyk,Ewa Gorczyńska,J. Maciej Zaucha,Krzysztof Kałwak +17 more
TL;DR: In this paper , a single-center experience in seven children with chemorefractory B-cell precursor acute lymphoblastic leukemia (r/r BCP-ALL) treated with blinatumomab before CAR-T cell therapy either to reduce disease burden before apheresis (six patients) or as a bridging therapy (two patients).
Journal ArticleDOI
Need for pneumococcal revaccination after blinatumomab therapy: A case report
TL;DR: In this article , a 27-month-old male with B-cell acute lymphoblastic leukemia (ALL) in first remission who received blinatumomab, subsequently developed recurrent Streptococcus pneumoniae bacteremias during maintenance, and was found to have diminished vaccine titer levels.
Journal ArticleDOI
Acute Lymphoblastic Leukemia Immunotherapy Treatment: Now, Next, and Beyond
TL;DR: A review of new treatment paradigms being used in the relapsed/refractory setting as well as current trials through which these new therapies might be introduced to the frontline setting is provided in this article .
Journal ArticleDOI
Immunotherapy for Pediatric Acute Lymphoblastic Leukemia: Recent Advances and Future Perspectives
TL;DR: This review will thoroughly discuss the emerging immunotherapeutics for the treatment of pediatric ALL, as well as side-effects and new development.
References
More filters
Journal ArticleDOI
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
TL;DR: Moher et al. as mentioned in this paper introduce PRISMA, an update of the QUOROM guidelines for reporting systematic reviews and meta-analyses, which is used in this paper.
Journal ArticleDOI
Immunophenotyping of blood lymphocytes in childhood: Reference values for lymphocyte subpopulations
W. Marieke Comans-Bitter,Ronald de Groot,René van den Beemd,Herman J. Neijens,Wim C. J. Hop,Kees Groeneveld,Herbert Hooijkaas,Jacques J.M. van Dongen +7 more
TL;DR: It is strongly recommended that immunophenotyping of blood lymphocytes for the diagnosis of hematologic and immunologic disorders be based on the absolute rather than on the relative size of lymphocyte subpopulations.
Journal ArticleDOI
A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial.
Rob Pieters,Martin Schrappe,Paola De Lorenzo,Ian Hann,Giulio Rossi,Maria S. Felice,Liisa Hovi,Thierry Leblanc,Tomasz Szczepański,Alina Ferster,Gritta Janka,Jeffrey E. Rubnitz,Lewis B. Silverman,Jan Stary,Myriam Campbell,Chi Kong Li,Georg Mann,Ram Suppiah,Andrea Biondi,Ajay Vora,Maria Grazia Valsecchi +20 more
TL;DR: Patients treated with the hybrid protocol, and especially those who responded poorly to prednisone, had higher EFS than most reported outcomes for treatment of infant ALL, and Delayed intensification of chemotherapy did not benefit patients.
Journal ArticleDOI
Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Arend von Stackelberg,Franco Locatelli,Gerhard Zugmaier,Rupert Handgretinger,Tanya M. Trippett,Carmelo Rizzari,Peter Bader,Maureen M. O'Brien,Benoit Brethon,Deepa Bhojwani,Paul G. Schlegel,Arndt Borkhardt,Susan R. Rheingold,Todd M. Cooper,Christian M. Zwaan,Phillip Barnette,Chiara Messina,Gérard Michel,Steven G. DuBois,Kuolung Hu,Min Zhu,James A. Whitlock,Lia Gore +22 more
TL;DR: This trial, which to the best of the authors' knowledge was the first such trial in pediatrics, demonstrated antileukemic activity of single-agent blinatumomab with complete minimal residual disease response in children with relapsed/refractory BCP-ALL.
Journal ArticleDOI
Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct
Patrick Hoffmann,Robert Hofmeister,Klaus Brischwein,Christian Brandl,Sandrine Crommer,Ralf C. Bargou,Christian Itin,Nadja Prang,Patrick A. Baeuerle +8 more
TL;DR: This is the first study showing that a bispecific antibody can sustain multiple rounds of target cell lysis by T cells, and it is suggested that the rate of serial killing was mostly determined by T‐cell movement and target cell scanning and lysis.
Related Papers (5)
Blinatumomab as a bridge to further therapy in cases of overwhelming toxicity in pediatric B-cell precursor acute lymphoblastic leukemia: Report from the Israeli Study Group of Childhood Leukemia.
Sarah Elitzur,Nira Arad-Cohen,Shlomit Barzilai-Birenboim,Miriam Ben-Harush,Bella Bielorai,Bella Bielorai,Ronit Elhasid,Tamar Feuerstein,Gil Gilad,Alexander Gural,Mira Kharit,Naomi Litichever,Ronit Nirel,Sigal Weinreb,Ofir Wolach,Ofir Wolach,Amos Toren,Amos Toren,Shai Izraeli,Elad Jacoby,Elad Jacoby +20 more